Cuorips Inc. (4894) AI Stock Analysis

• Market Cap: ¥65.25B
• Dividend Yield: N/A
• Average Volume (3M): 107.56K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.16
• Revenue Growth: 1772.85%
• EPS Growth: 16.16%
• Country: JP
• Employees: 59
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -34.47
• Shares Outstanding: 8,265,366
• 10 Day Avg. Volume: 98,200
• 30 Day Avg. Volume: 107,556
• PEG Ratio: 16.56
• Price to Book (P/B): 12.03
• Price to Sales (P/S): 379.55
• P/FCF Ratio: -74.48
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: ¥8,241.00 ▲(32.28% Upside)

The score is held back primarily by persistent heavy losses and significant cash burn, despite strong revenue growth and a debt-free balance sheet that provides runway. Technicals are supportive due to a strong uptrend, but overbought signals temper the near-term outlook. Valuation is also constrained by negative earnings and no provided dividend yield.

Positive Factors

Rapid Revenue Growth

Steep revenue expansion indicates genuine commercial traction and expanding market acceptance of products. Over a 2-6 month horizon this growth underpins scale benefits, supports broader customer adoption, and provides a foundation for future operating leverage if cost growth is controlled.

Healthy Gross Margin

A ~52% gross margin reflects strong unit economics and pricing power for core offerings. Sustained margin levels give the business structural capacity to absorb SG&A and R&D as it scales, improving odds of eventual profitability once fixed costs are leveraged over larger revenue.

Conservative Balance Sheet

A debt-free, equity-funded balance sheet provides meaningful financial flexibility and lowers refinancing risk. This structural strength lengthens runway to execute strategic initiatives, supports R&D and commercialization spend, and reduces short-term liquidity pressure from interest obligations.

Negative Factors

Large Cash Burn

Consistently large negative operating and free cash flow denotes a high burn profile that erodes reserves and raises funding risk. Over months this increases likelihood of dilutive capital raises or cutbacks, constraining investment in commercialization and product development.

Sustained Operating Losses

Deep and persistent operating losses show the current cost structure outpaces revenue, signaling an unclear path to break-even absent material margin improvement. Structurally, ongoing losses impair reinvestment capacity and elevate execution risk for longer-term growth plans.

Negative Return on Equity

A negative ROE indicates the company is destroying shareholder value rather than generating returns on invested equity. Persisting at this level undermines investor confidence, complicates non-dilutive financing access, and pressures management to materially improve profitability or capital efficiency.

Cuorips Inc. Business Overview & Revenue Model

Company Description

Cuorips Inc. engages in the research, development, manufacture, commercialization, and sale of iPS cell-derived cardiomyocyte sheets. The company offers cellular and tissue-based, and cell processing products. It also provides contract development and manufacturing, and consulting services. The company was formerly known as Cuore Inc. and changed its name to Cuorips Inc. in June 2017. Cuorips Inc. was incorporated in 2017 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Cuorips Inc. generates revenue through the development and commercialization of regenerative medicine products targeting cardiac diseases. The company makes money by licensing its proprietary technologies and therapies to pharmaceutical and biotechnology companies. Additionally, Cuorips Inc. may receive funding through collaborative research agreements and partnerships with healthcare institutions and academic entities. Revenue streams could also include milestone payments and royalties from successfully developed and marketed therapies. The company's earnings are significantly influenced by its ability to advance its pipeline products through clinical trials and secure regulatory approvals.

Cuorips Inc. Financial Statement Overview

Summary

Revenue growth is strong (+~404% to ~¥175m) with a solid gross margin (~52%) and a debt-free balance sheet with meaningful equity (~¥5.5b). However, operating and net losses remain very large (EBIT ~-¥590m; net ~-¥644m) and cash burn is heavy (operating CF ~-¥813m; FCF ~-¥893m), keeping financial risk elevated until breakeven visibility improves.

Income Statement

Revenue has scaled sharply in the latest year (2025 annual revenue up ~404% to ~¥175m), and gross margin remains solid (~52%). However, profitability is very weak: operating losses remain extremely large (EBIT about -¥590m) and net losses deepened to about -¥644m, leaving net margin highly negative. Overall, the company shows early commercial traction but still lacks a clear path to operating breakeven based on the current cost structure.

Balance Sheet

The balance sheet is conservatively levered with zero reported debt and meaningful equity (~¥5.5b) supporting a largely equity-funded profile. That said, returns remain negative (return on equity around -11.7% in 2025), indicating ongoing value dilution risk if losses persist. Overall financial flexibility looks good, but sustained losses continue to pressure long-term capital efficiency.

Cash Flow

Cash generation is weak, with operating cash flow negative and worsening in 2025 (about -¥813m), and free cash flow also deeply negative (about -¥893m), implying a high cash burn profile. Free cash flow is consistently negative relative to net income (free cash flow to net income > 1), suggesting losses are translating into real cash outflows rather than being primarily non-cash. The key strength is consistency of reporting and a lack of debt-related cash burden, but the burn rate remains the central risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	260.31M	175.21M	23.10M	38.28M	13.91M	220.00K
Gross Profit	119.12M	91.56M	9.63M	21.01M	10.65M	138.00K
EBITDA	-570.19M	-565.32M	-518.00M	-371.78M	-280.40M	-221.17M
Net Income	-652.25M	-644.34M	-632.18M	-452.08M	-375.34M	-307.83M
Balance Sheet
Total Assets	5.75B	5.74B	6.18B	3.59B	4.04B	4.36B
Cash, Cash Equivalents and Short-Term Investments	4.85B	4.79B	5.58B	2.94B	3.34B	3.54B
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	324.59M	211.91M	200.96M	133.79M	149.36M	141.95M
Stockholders Equity	5.42B	5.53B	5.98B	3.45B	3.90B	4.22B
Cash Flow
Free Cash Flow	0.00	-892.81M	-487.01M	-412.18M	-249.45M	-950.97M
Operating Cash Flow	0.00	-812.62M	-451.06M	-401.61M	-220.76M	-282.80M
Investing Cash Flow	0.00	-119.99M	-35.00M	-8.97M	-28.44M	-670.21M
Financing Cash Flow	0.00	145.11M	3.13B	10.69M	48.54M	3.77B

Cuorips Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6230.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4894, the sentiment is Positive. The current price of 6230 is below the 20-day moving average (MA) of 7637.00, below the 50-day MA of 6697.60, and below the 200-day MA of 6637.10, indicating a bullish trend. The MACD of 389.27 indicates Positive momentum. The RSI at 58.76 is Neutral, neither overbought nor oversold. The STOCH value of 51.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4894.

Cuorips Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7774	57 Neutral	¥21.93B	-47.52	―	―	-5.65%	-469.19%
4894	55 Neutral	¥65.25B	-97.23	―	―	1772.85%	16.16%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4575	47 Neutral	¥17.17B	-13.92	―	―	―	14.03%
4889	46 Neutral	¥19.61B	542.68	―	―	-32.68%	―
4593	45 Neutral	¥44.21B	-9.72	―	―	-82.33%	47.73%
4599	43 Neutral	¥18.18B	-9.50	―	―	―	11.34%